With the spike in COVID-19 cases worldwide, there is an increasing amount of people who are seeking precautionary vaccines for respiratory issues in preparation for the winter. Merck’s Pneumovax 23, more specifically, has hit record high sale volumes worldwide in the second quarter reaching $96 million in revenue. Pneumococcal vaccines are becoming rationed in Europe as many people seek protection from the effects of COVID-19.
Read more here.
More on: News Regulatory